Published in Gene Therapy Weekly, April 24th, 1995
The Phase I/II clinical trial, which is expected to enroll 25 patients with advanced solid malignancies or lymphoma, is the company's second gene therapy product candidate to enter clinical trials. Dr. Evan Hersh is the principal investigator for the trial, which will evaluate the safety and biological activity of the experimental gene therapy.
Earlier in 1995, Vical received the necessary allowances from the U.S. National Institutes of Health (NIH) Recombinant Advisory...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.